カテゴリ： Market Monitor Global, 世界, 医療/バイオ

アルコール性肝障害治療薬のグローバル市場展望 2023年-2029年：動物性原料ベース、植物性原料ベース

■ 英語タイトル：Hepatoprotective Drug Against Alcohol Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23JU5614）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23JU5614
■ 発行日：2023年6月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆医療
■ ページ数：77
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[アルコール性肝障害治療薬のグローバル市場展望 2023年-2029年：動物性原料ベース、植物性原料ベース]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界のアルコール性肝障害治療薬市場規模と予測を収録しています。・世界のアルコール性肝障害治療薬市場：売上、2018年-2023年、2024年-2029年
・世界のアルコール性肝障害治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のアルコール性肝障害治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「動物性原料ベース」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

アルコール性肝障害治療薬のグローバル主要企業は、Livestamin Healthcare、 The Himalaya Drug Company、 Mysha Health World、 Chambio、 Noreva Biotech、 Finecure Pharmaceuticals Limited、 Iscon Life Sciences、 Sunflower Pharmaceutical Group Co.,ltd.、 Swisse、 By-health Co.,ltd、 Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.、 Xiuzheng Pharmaceutical Industry Group Companyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、アルコール性肝障害治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のアルコール性肝障害治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界のアルコール性肝障害治療薬市場：タイプ別市場シェア、2022年
・動物性原料ベース、植物性原料ベース

世界のアルコール性肝障害治療薬市場：用途別、2018年-2023年、2024年-2029年
世界のアルコール性肝障害治療薬市場：用途別市場シェア、2022年
・薬局、病院、栄養クリニック、スーパー、その他

世界のアルコール性肝障害治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界のアルコール性肝障害治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるアルコール性肝障害治療薬のグローバル売上、2018年-2023年
・主要企業におけるアルコール性肝障害治療薬のグローバル売上シェア、2022年
・主要企業におけるアルコール性肝障害治療薬のグローバル販売量、2018年-2023年
・主要企業におけるアルコール性肝障害治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Livestamin Healthcare、 The Himalaya Drug Company、 Mysha Health World、 Chambio、 Noreva Biotech、 Finecure Pharmaceuticals Limited、 Iscon Life Sciences、 Sunflower Pharmaceutical Group Co.,ltd.、 Swisse、 By-health Co.,ltd、 Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.、 Xiuzheng Pharmaceutical Industry Group Company

*************************************************************

・調査・分析レポートの概要
アルコール性肝障害治療薬市場の定義
市場セグメント
世界のアルコール性肝障害治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のアルコール性肝障害治療薬市場規模
世界のアルコール性肝障害治療薬市場規模：2022年 VS 2029年
世界のアルコール性肝障害治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのアルコール性肝障害治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のアルコール性肝障害治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：動物性原料ベース、植物性原料ベース
アルコール性肝障害治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：薬局、病院、栄養クリニック、スーパー、その他
アルコール性肝障害治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別アルコール性肝障害治療薬市場規模 2022年と2029年
地域別アルコール性肝障害治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Livestamin Healthcare、 The Himalaya Drug Company、 Mysha Health World、 Chambio、 Noreva Biotech、 Finecure Pharmaceuticals Limited、 Iscon Life Sciences、 Sunflower Pharmaceutical Group Co.,ltd.、 Swisse、 By-health Co.,ltd、 Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.、 Xiuzheng Pharmaceutical Industry Group Company
...

This report aims to provide a comprehensive presentation of the global market for Hepatoprotective Drug Against Alcohol, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatoprotective Drug Against Alcohol. This report contains market size and forecasts of Hepatoprotective Drug Against Alcohol in global, including the following market information:
Global Hepatoprotective Drug Against Alcohol Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Hepatoprotective Drug Against Alcohol Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Hepatoprotective Drug Against Alcohol companies in 2022 (%)
The global Hepatoprotective Drug Against Alcohol market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Based on Animal Ingredients Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hepatoprotective Drug Against Alcohol include Livestamin Healthcare, The Himalaya Drug Company, Mysha Health World, Chambio, Noreva Biotech, Finecure Pharmaceuticals Limited, Iscon Life Sciences, Sunflower Pharmaceutical Group Co.,ltd. and Swisse, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hepatoprotective Drug Against Alcohol manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hepatoprotective Drug Against Alcohol Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hepatoprotective Drug Against Alcohol Market Segment Percentages, by Type, 2022 (%)
Based on Animal Ingredients
Based on Plant Ingredients
Global Hepatoprotective Drug Against Alcohol Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hepatoprotective Drug Against Alcohol Market Segment Percentages, by Application, 2022 (%)
Pharmacy
Hospital
Dieticians Clinic
Supermarket
Others
Global Hepatoprotective Drug Against Alcohol Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hepatoprotective Drug Against Alcohol Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hepatoprotective Drug Against Alcohol revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Hepatoprotective Drug Against Alcohol revenues share in global market, 2022 (%)
Key companies Hepatoprotective Drug Against Alcohol sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Hepatoprotective Drug Against Alcohol sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Livestamin Healthcare
The Himalaya Drug Company
Mysha Health World
Chambio
Noreva Biotech
Finecure Pharmaceuticals Limited
Iscon Life Sciences
Sunflower Pharmaceutical Group Co.,ltd.
Swisse
By-health Co.,ltd
Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.
Xiuzheng Pharmaceutical Industry Group Company
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hepatoprotective Drug Against Alcohol, market overview.
Chapter 2: Global Hepatoprotective Drug Against Alcohol market size in revenue and volume.
Chapter 3: Detailed analysis of Hepatoprotective Drug Against Alcohol manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hepatoprotective Drug Against Alcohol in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Hepatoprotective Drug Against Alcohol capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Hepatoprotective Drug Against Alcohol Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hepatoprotective Drug Against Alcohol Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hepatoprotective Drug Against Alcohol Overall Market Size
2.1 Global Hepatoprotective Drug Against Alcohol Market Size: 2022 VS 2029
2.2 Global Hepatoprotective Drug Against Alcohol Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Hepatoprotective Drug Against Alcohol Sales: 2018-2029
3 Company Landscape
3.1 Top Hepatoprotective Drug Against Alcohol Players in Global Market
3.2 Top Global Hepatoprotective Drug Against Alcohol Companies Ranked by Revenue
3.3 Global Hepatoprotective Drug Against Alcohol Revenue by Companies
3.4 Global Hepatoprotective Drug Against Alcohol Sales by Companies
3.5 Global Hepatoprotective Drug Against Alcohol Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Hepatoprotective Drug Against Alcohol Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Hepatoprotective Drug Against Alcohol Product Type
3.8 Tier 1, Tier 2 and Tier 3 Hepatoprotective Drug Against Alcohol Players in Global Market
3.8.1 List of Global Tier 1 Hepatoprotective Drug Against Alcohol Companies
3.8.2 List of Global Tier 2 and Tier 3 Hepatoprotective Drug Against Alcohol Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Hepatoprotective Drug Against Alcohol Market Size Markets, 2022 & 2029
4.1.2 Based on Animal Ingredients
4.1.3 Based on Plant Ingredients
4.2 By Type – Global Hepatoprotective Drug Against Alcohol Revenue & Forecasts
4.2.1 By Type – Global Hepatoprotective Drug Against Alcohol Revenue, 2018-2023
4.2.2 By Type – Global Hepatoprotective Drug Against Alcohol Revenue, 2024-2029
4.2.3 By Type – Global Hepatoprotective Drug Against Alcohol Revenue Market Share, 2018-2029
4.3 By Type – Global Hepatoprotective Drug Against Alcohol Sales & Forecasts
4.3.1 By Type – Global Hepatoprotective Drug Against Alcohol Sales, 2018-2023
4.3.2 By Type – Global Hepatoprotective Drug Against Alcohol Sales, 2024-2029
4.3.3 By Type – Global Hepatoprotective Drug Against Alcohol Sales Market Share, 2018-2029
4.4 By Type – Global Hepatoprotective Drug Against Alcohol Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Hepatoprotective Drug Against Alcohol Market Size, 2022 & 2029
5.1.2 Pharmacy
5.1.3 Hospital
5.1.4 Dieticians Clinic
5.1.5 Supermarket
5.1.6 Others
5.2 By Application – Global Hepatoprotective Drug Against Alcohol Revenue & Forecasts
5.2.1 By Application – Global Hepatoprotective Drug Against Alcohol Revenue, 2018-2023
5.2.2 By Application – Global Hepatoprotective Drug Against Alcohol Revenue, 2024-2029
5.2.3 By Application – Global Hepatoprotective Drug Against Alcohol Revenue Market Share, 2018-2029
5.3 By Application – Global Hepatoprotective Drug Against Alcohol Sales & Forecasts
5.3.1 By Application – Global Hepatoprotective Drug Against Alcohol Sales, 2018-2023
5.3.2 By Application – Global Hepatoprotective Drug Against Alcohol Sales, 2024-2029
5.3.3 By Application – Global Hepatoprotective Drug Against Alcohol Sales Market Share, 2018-2029
5.4 By Application – Global Hepatoprotective Drug Against Alcohol Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Hepatoprotective Drug Against Alcohol Market Size, 2022 & 2029
6.2 By Region – Global Hepatoprotective Drug Against Alcohol Revenue & Forecasts
6.2.1 By Region – Global Hepatoprotective Drug Against Alcohol Revenue, 2018-2023
6.2.2 By Region – Global Hepatoprotective Drug Against Alcohol Revenue, 2024-2029
6.2.3 By Region – Global Hepatoprotective Drug Against Alcohol Revenue Market Share, 2018-2029
6.3 By Region – Global Hepatoprotective Drug Against Alcohol Sales & Forecasts
6.3.1 By Region – Global Hepatoprotective Drug Against Alcohol Sales, 2018-2023
6.3.2 By Region – Global Hepatoprotective Drug Against Alcohol Sales, 2024-2029
6.3.3 By Region – Global Hepatoprotective Drug Against Alcohol Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Hepatoprotective Drug Against Alcohol Revenue, 2018-2029
6.4.2 By Country – North America Hepatoprotective Drug Against Alcohol Sales, 2018-2029
6.4.3 US Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.4.4 Canada Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.4.5 Mexico Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Hepatoprotective Drug Against Alcohol Revenue, 2018-2029
6.5.2 By Country – Europe Hepatoprotective Drug Against Alcohol Sales, 2018-2029
6.5.3 Germany Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.5.4 France Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.5.5 U.K. Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.5.6 Italy Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.5.7 Russia Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.5.8 Nordic Countries Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.5.9 Benelux Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Hepatoprotective Drug Against Alcohol Revenue, 2018-2029
6.6.2 By Region – Asia Hepatoprotective Drug Against Alcohol Sales, 2018-2029
6.6.3 China Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.6.4 Japan Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.6.5 South Korea Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.6.6 Southeast Asia Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.6.7 India Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Hepatoprotective Drug Against Alcohol Revenue, 2018-2029
6.7.2 By Country – South America Hepatoprotective Drug Against Alcohol Sales, 2018-2029
6.7.3 Brazil Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.7.4 Argentina Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Hepatoprotective Drug Against Alcohol Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Hepatoprotective Drug Against Alcohol Sales, 2018-2029
6.8.3 Turkey Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.8.4 Israel Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.8.5 Saudi Arabia Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
6.8.6 UAE Hepatoprotective Drug Against Alcohol Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Livestamin Healthcare
7.1.1 Livestamin Healthcare Company Summary
7.1.2 Livestamin Healthcare Business Overview
7.1.3 Livestamin Healthcare Hepatoprotective Drug Against Alcohol Major Product Offerings
7.1.4 Livestamin Healthcare Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.1.5 Livestamin Healthcare Key News & Latest Developments
7.2 The Himalaya Drug Company
7.2.1 The Himalaya Drug Company Company Summary
7.2.2 The Himalaya Drug Company Business Overview
7.2.3 The Himalaya Drug Company Hepatoprotective Drug Against Alcohol Major Product Offerings
7.2.4 The Himalaya Drug Company Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.2.5 The Himalaya Drug Company Key News & Latest Developments
7.3 Mysha Health World
7.3.1 Mysha Health World Company Summary
7.3.2 Mysha Health World Business Overview
7.3.3 Mysha Health World Hepatoprotective Drug Against Alcohol Major Product Offerings
7.3.4 Mysha Health World Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.3.5 Mysha Health World Key News & Latest Developments
7.4 Chambio
7.4.1 Chambio Company Summary
7.4.2 Chambio Business Overview
7.4.3 Chambio Hepatoprotective Drug Against Alcohol Major Product Offerings
7.4.4 Chambio Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.4.5 Chambio Key News & Latest Developments
7.5 Noreva Biotech
7.5.1 Noreva Biotech Company Summary
7.5.2 Noreva Biotech Business Overview
7.5.3 Noreva Biotech Hepatoprotective Drug Against Alcohol Major Product Offerings
7.5.4 Noreva Biotech Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.5.5 Noreva Biotech Key News & Latest Developments
7.6 Finecure Pharmaceuticals Limited
7.6.1 Finecure Pharmaceuticals Limited Company Summary
7.6.2 Finecure Pharmaceuticals Limited Business Overview
7.6.3 Finecure Pharmaceuticals Limited Hepatoprotective Drug Against Alcohol Major Product Offerings
7.6.4 Finecure Pharmaceuticals Limited Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.6.5 Finecure Pharmaceuticals Limited Key News & Latest Developments
7.7 Iscon Life Sciences
7.7.1 Iscon Life Sciences Company Summary
7.7.2 Iscon Life Sciences Business Overview
7.7.3 Iscon Life Sciences Hepatoprotective Drug Against Alcohol Major Product Offerings
7.7.4 Iscon Life Sciences Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.7.5 Iscon Life Sciences Key News & Latest Developments
7.8 Sunflower Pharmaceutical Group Co.,ltd.
7.8.1 Sunflower Pharmaceutical Group Co.,ltd. Company Summary
7.8.2 Sunflower Pharmaceutical Group Co.,ltd. Business Overview
7.8.3 Sunflower Pharmaceutical Group Co.,ltd. Hepatoprotective Drug Against Alcohol Major Product Offerings
7.8.4 Sunflower Pharmaceutical Group Co.,ltd. Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.8.5 Sunflower Pharmaceutical Group Co.,ltd. Key News & Latest Developments
7.9 Swisse
7.9.1 Swisse Company Summary
7.9.2 Swisse Business Overview
7.9.3 Swisse Hepatoprotective Drug Against Alcohol Major Product Offerings
7.9.4 Swisse Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.9.5 Swisse Key News & Latest Developments
7.10 By-health Co.,ltd
7.10.1 By-health Co.,ltd Company Summary
7.10.2 By-health Co.,ltd Business Overview
7.10.3 By-health Co.,ltd Hepatoprotective Drug Against Alcohol Major Product Offerings
7.10.4 By-health Co.,ltd Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.10.5 By-health Co.,ltd Key News & Latest Developments
7.11 Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.
7.11.1 Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. Company Summary
7.11.2 Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. Hepatoprotective Drug Against Alcohol Business Overview
7.11.3 Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. Hepatoprotective Drug Against Alcohol Major Product Offerings
7.11.4 Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.11.5 Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. Key News & Latest Developments
7.12 Xiuzheng Pharmaceutical Industry Group Company
7.12.1 Xiuzheng Pharmaceutical Industry Group Company Company Summary
7.12.2 Xiuzheng Pharmaceutical Industry Group Company Hepatoprotective Drug Against Alcohol Business Overview
7.12.3 Xiuzheng Pharmaceutical Industry Group Company Hepatoprotective Drug Against Alcohol Major Product Offerings
7.12.4 Xiuzheng Pharmaceutical Industry Group Company Hepatoprotective Drug Against Alcohol Sales and Revenue in Global (2018-2023)
7.12.5 Xiuzheng Pharmaceutical Industry Group Company Key News & Latest Developments
8 Global Hepatoprotective Drug Against Alcohol Production Capacity, Analysis
8.1 Global Hepatoprotective Drug Against Alcohol Production Capacity, 2018-2029
8.2 Hepatoprotective Drug Against Alcohol Production Capacity of Key Manufacturers in Global Market
8.3 Global Hepatoprotective Drug Against Alcohol Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Hepatoprotective Drug Against Alcohol Supply Chain Analysis
10.1 Hepatoprotective Drug Against Alcohol Industry Value Chain
10.2 Hepatoprotective Drug Against Alcohol Upstream Market
10.3 Hepatoprotective Drug Against Alcohol Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Hepatoprotective Drug Against Alcohol Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • アルコール飲酒検知器&薬物検査装置のグローバル市場展望 2023年-2029年：卓上型、可動型、手持ち型
  • 軟骨無形成術治療薬のグローバル市場展望 2023年-2029年：RBM-007、TA-46、B-701、その他
  • アルコールテスターのグローバル市場展望 2023年-2029年：卓上型、可動型、手持ち型
  • 生殖補助医療用薬剤のグローバル市場展望 2023年-2029年：ゴナドトロピン放出ホルモン、卵胞刺激ホルモン、ヒトコロイック性ゴナドトロピン、プロゲストーゲンホルモン
  • 抗精神病薬のグローバル市場展望 2023年-2029年：第一世代抗精神病薬、第二世代抗精神病薬、第三世代抗精神病薬
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23JU5614 )"アルコール性肝障害治療薬のグローバル市場展望 2023年-2029年：動物性原料ベース、植物性原料ベース" (英文：Hepatoprotective Drug Against Alcohol Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。